业务新闻

GEA opens a new chapter for biopharmaceutical separation processes with pharma separator lines aseptic and pure

06 Jul 2021

With the introduction of the new separator lines aseptic and pure under the motto "Energizing Pharma", pharmaceutical specialist GEA is ushering in a new era for biopharmaceutical separation processes.

GEA's aseptic separator line offers customers with highly hygienic processes gentle processing of, for example, human and veterinary vaccines, monoclonal antibodies (mAb), e-coli, insulin, starter cultures and probiotic products. (Photo: GEA)

GEA's aseptic separator line offers customers with highly hygienic processes gentle processing of, for example, human and veterinary vaccines, monoclonal antibodies (mAb), e-coli, insulin, starter cultures and probiotic products. (Photo: GEA)

Based on GEA's decades of expertise in the field of mechanical separation technology, GEA engineers have developed a new, fully comprehensive portfolio of plug & produce pharma separator systems that moves harmoniously and perfectly between individual and process-related requirements and leaves nothing to be desired. The separator lines aseptic and pure are used in all pharmaceutical and biotechnological downstream processes. GEA's aseptic separator line offers customers with highly hygienic processes gentle processing of, for example, human and veterinary vaccines, monoclonal antibodies (mAb), e-coli, insulin, starter cultures and probiotic products. The pure line is used in applications with varying hygienic requirements such as nutritional supplements, therapeutic proteins, pharmaceutical extractions, and extracellular and intracellular enzyme recovery.

Perfectly adapted separation solution from GEA

The biopharmaceutical industry is united by a common denominator. It places the highest value on uncompromising hygienic design, process reliability and high yield. However, the detailed requirements can vary widely depending on process regulations and specifications. GEA took this requirement profile as an opportunity to develop a separation solution for the biopharmaceutical industry that is perfectly adaptable in every respect.

Line pure is used in applications with varying hygienic requirements such as dietary supplements, therapeutic proteins, pharmaceutical extractions, and extracellular and intracellular enzyme recovery. (Photo: GEA)

Line pure is used in applications with varying hygienic requirements such as dietary supplements, therapeutic proteins, pharmaceutical extractions, and extracellular and intracellular enzyme recovery. (Photo: GEA)

Development to the highest GEA standards

The new pharmaceutical separator lines "aseptic" and "pure" were developed to the highest GEA standards at the German GEA Westfalia Separator plant in Oelde, where they are built and tested. The aseptic line stands for the highest hygienic pharmaceutical requirements. The pure line provides maximum variability and is perfectly tailored to the diverse process requirements of the biopharmaceutical industry. All functions for pharmaceutical cleanliness requirements such as an automatic CIP (Cleaning-in-Place), SIP (Steam Sterilization in Place), simple validation and a high-end qualification package are included. In addition, with the help of the cGMP validation process ("Current Good Manufacturing Practice, cGMP), the pharma separators support GEA customers in their quality standard reviews.

Contact

Dr. Michael Golek

Phone: 49 211 9136 1505

Media Relations

GEA Group Aktiengesellschaft

Peter-Müller-Str. 12


40468

Düsseldorf


Germany

+49 211 9136-0

About GEA

GEA 是食品加工行业及众多工业领域的领先供应商之一,2019 年的销售总额约达 49 亿欧元。

作为国际技术集团,我们专注于机械制造,生产运营,工艺技术及其设备组件。 GEA 为各种终端用户市场的复杂生产流程提供可持续的能源解决方案,并提供全面的服务组合。集团在长期持续增长的食品和饮料行业的收入约占其总收入的 70%。截至 2018 年 12 月 31 日,集团的全球员工已超过 18,500 人。GEA 在其业务领域中是市场和技术领导者。GEA 是德国 MDAX 上市公司(G1A,WKN 660 200),拥有 STOXX® Europe 600 指数和优选的 MSCI 全球可持续发展指数。
接收 GEA 新闻

订阅 GEA 的新闻,掌握 GEA 的创新信息和故事。

联系我们

我们随时为您提供帮助!您只需提供少量详细信息,我们就能回复您的查询。